Calibration of transition probabilities to model survival of adjuvant trastuzumab for early breast cancer in Indonesia
International Journal of Technology Assessment in Health Care · 2025
DOI: 10.1017/s0266462325000157 ↗Kurz gefasst
Evaluationsstudie in der Zeitschrift International Journal of Technology Assessment in Health Care, 2025. Verfasst von Arie Rahadi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Management Sciences for Health, Arlington, VA, USA. Hauptthemen laut MEDLINE: Chemotherapy, Adjuvant, Markov Chains, Breast Neoplasms, Trastuzumab. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: United States Agency for International Development.
Abstract (Originalsprache)
Objectives
Cost-effectiveness models fully informed by real-world epidemiological parameters yield the best results, but they are costly to obtain. Model calibration using real-world data/evidence (RWD/E) on routine health indicators can provide an alternative to improve the validity and acceptability of the results. We calibrated the transition probabilities of the reference chemotherapy treatment using RWE on patient overall survival (OS) to model the survival benefit of adjuvant trastuzumab in Indonesia.
Methods
A Markov model comprising four health states was initially parameterized using the reference-treatment transition probabilities, obtained from published international evidence. We then calibrated these probabilities, targeting a 2-year OS of 86.11 percent from the RWE sourced from hospital registries. We compared projected OS duration and life-years gained (LYG) before and after calibration for the Nelder–Mead, Bound Optimization BY Quadratic Approximation, and generalized reduced gradient (GRG) nonlinear optimization methods.
Results
The pre-calibrated transition probabilities overestimated the 2-year OS (92.25 percent). GRG nonlinear performed best and had the smallest difference with the RWD/E OS. After calibration, the projected OS duration was significantly lower than their pre-calibrated estimates across all optimization methods for both standard chemotherapy (~7.50 vs. 11.00 years) and adjuvant trastuzumab (~9.50 vs. 12.94 years). LYG measures were, however, similar (~2 years) for the pre-calibrated and calibrated models.
Conclusions
RWD/E calibration resulted in realistically lower survival estimates. Despite the little difference in LYG, calibration is useful to adapt external evidence commonly used to derive transition probabilities to the policy context, thereby enhancing the validity and acceptability of the modeling results.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Management Sciences for Health, Arlington, VA, USA.
- Center for Health Financing Policy and Insurance Management, Gadjah Mada University, Sleman, Yogyakarta, Indonesia.
- Center for Health Financing and Decentralization Policy, Ministry of Health Republic of Indonesia, Central Jakarta, Jakarta, Indonesia.
ORCID-Profile: Arie Rahadi
Förderung
- United States Agency for International Development
Zitieren
APA
Rahadi, A., Mahardya, R. T. K., Listiani, P., Herlinawaty, E., Nugraha, R. R., Budiman, D. R., & Suharlim, C. (2025). Calibration of transition probabilities to model survival of adjuvant trastuzumab for early breast cancer in Indonesia. International Journal of Technology Assessment in Health Care. https://doi.org/10.1017/s0266462325000157
Vancouver
Rahadi A, Mahardya RTK, Listiani P, Herlinawaty E, Nugraha RR, Budiman DR, et al. Calibration of transition probabilities to model survival of adjuvant trastuzumab for early breast cancer in Indonesia. International Journal of Technology Assessment in Health Care. 2025. doi:10.1017/s0266462325000157
BibTeX
@article{Rahadi2025,
author = {Rahadi, Arie and Mahardya, Rizki Tsalatshita Khair and Listiani, Putri and Herlinawaty, Eva and Nugraha, Ryan Rachmad and Budiman, Dani Ramdhani and Suharlim, Christian},
title = {Calibration of transition probabilities to model survival of adjuvant trastuzumab for early breast cancer in Indonesia},
journal = {International Journal of Technology Assessment in Health Care},
year = {2025},
doi = {10.1017/s0266462325000157}
}
EUVIMED